Pulse Biosciences Inc (PLSE) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access PLSE Annual Balance Sheets →
Balance sheet performance over multiple periods helps investors evaluate the financial resilience of Pulse Biosciences Inc.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent101.62
Cash & Short-term Investments101.00
Accounts receivable0.12
Inventories0.24
Other Current Assets0.00
Prepaid Expense And Other Assets Current3.72
Total Current Assets105.70
Equipment/Property/Plant Net1.06
Goodwill net2.79
Intangible Assets0.22
Other Assets, Noncurrent5.79
Operating Lease Right Of Use Asset5.70
Total Assets115.56
Liabilities
Accounts Payable, Current AC2.83
Accrued Liabilities, Current AC6.46
Other Liabilities, Current1.69
Total Current Liabilities10.98
Total Long-term Debt0.00
Financial Instruments, Insurance, Noncurrent0.21
Other liabilities, Noncurrent4.88
OperatingLeaseLiabilityNoncurrent5.53
Operating Lease Liability Current1.63
Total Liabilities16.06
Stockholders' Equity
Common Stock Value0.07
Additional Paid In Capital Common Stock605.95
Retained Earnings / Accumulated Deficit-506.52
Other Equity0.00
Common Stockholder's Equity99.50
Total Stockholder's Equity99.50
Liabilities & Stockholder's Equity115.56
4 historic quarters locked

Sign in to unlock the full Pulse Biosciences Inc balance sheet history.

About Pulse Biosciences Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001437749-26-026288

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.